These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 34752963)
1. Decompensation in Patients With Advanced NAFLD: More Questions That Need Answering. Giri S; Sundaram S Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2154-2155. PubMed ID: 34752963 [No Abstract] [Full Text] [Related]
2. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796 [TBL] [Abstract][Full Text] [Related]
3. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516 [TBL] [Abstract][Full Text] [Related]
4. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. Allen AM; Therneau TM; Ahmed OT; Gidener T; Mara KC; Larson JJ; Canning RE; Benson JT; Kamath PS J Hepatol; 2022 Nov; 77(5):1237-1245. PubMed ID: 35843374 [TBL] [Abstract][Full Text] [Related]
5. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). Johnston MP; Patel J; Byrne CD Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662 [TBL] [Abstract][Full Text] [Related]
6. Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease. Ahmed HS; Pedersen N; Jayanna MB; Ten Eyck P; Sanchez A; Murali AR J Gen Intern Med; 2020 May; 35(5):1523-1529. PubMed ID: 32157645 [TBL] [Abstract][Full Text] [Related]
7. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas. Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595 [TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. Stål P World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963 [TBL] [Abstract][Full Text] [Related]
9. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831 [TBL] [Abstract][Full Text] [Related]
10. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795 [TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515 [TBL] [Abstract][Full Text] [Related]
13. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Tasneem AA; Luck NH; Majid Z Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775 [TBL] [Abstract][Full Text] [Related]
14. Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease. Paternostro R; Kwanten WJ; Reiberger T J Hepatol; 2023 Mar; 78(3):e102-e104. PubMed ID: 36070837 [No Abstract] [Full Text] [Related]
15. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. Caussy C; Soni M; Cui J; Bettencourt R; Schork N; Chen CH; Ikhwan MA; Bassirian S; Cepin S; Gonzalez MP; Mendler M; Kono Y; Vodkin I; Mekeel K; Haldorson J; Hemming A; Andrews B; Salotti J; Richards L; Brenner DA; Sirlin CB; Loomba R; J Clin Invest; 2017 Jun; 127(7):2697-2704. PubMed ID: 28628033 [TBL] [Abstract][Full Text] [Related]
16. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study. Bassegoda O; Rivera-Esteban J; Serra I; Morillas R; Broquetas T; Vergara M; Rodriguez A; Aracil C; Virolés S; Carrión JA; Pardo A; Rodríguez-Tajes S; Serra-Burriel M; Pericàs JM; Augustin S; Ginès P; Graupera I Hepatol Commun; 2022 Nov; 6(11):3212-3222. PubMed ID: 36073343 [TBL] [Abstract][Full Text] [Related]
17. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Cichoż-Lach H; Celiński K; Prozorow-Król B; Swatek J; Słomka M; Lach T Med Sci Monit; 2012 Dec; 18(12):CR735-40. PubMed ID: 23197236 [TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. Petta S; Sebastiani G; Bugianesi E; Viganò M; Wong VW; Berzigotti A; Fracanzani AL; Anstee QM; Marra F; Barbara M; Calvaruso V; Cammà C; Di Marco V; Craxì A; de Ledinghen V J Hepatol; 2018 Oct; 69(4):878-885. PubMed ID: 29802949 [TBL] [Abstract][Full Text] [Related]